



SpeedX launch next generation PCR multiplexing technology
Inaugural RespiV **PlexPlus**® product showcases advantages

SYDNEY, AUSTRALIA – (8th April 2024) SpeedX unveils a new innovative spin on qPCR technology that doubles the standard target output. Without requiring specialized equipment, the new **PlexPlus**® technology does all the work whilst utilizing existing standard qPCR instrumentation in laboratories.

PCR is the gold standard for detecting infections like respiratory. However, current laboratory solutions can be expensive, sometimes covering unnecessary targets, and are often ill-suited to meet high testing demands. Applying an innovative approach to standard PCR, SpeedX has developed **PlexPlus**®, a highly multiplexed, scalable technology that is affordable.

The **PlexPlus**® technology allows detection of multiple target readouts within each channel during qPCR, enhancing the multiplexing capacity and enabling higher sample throughput. The innovation comes from specialized universal probes, which fluoresce in a temperature-dependent manner, with their fluorescence acquired at two temperatures across multiple wavelengths in real time.

"I love creating new tech and pushing PCR boundaries!" **Alison Todd, co-founder, and Chief Technical Officer, SpeedX**, exclaimed. "Our assays powered with **PlexPlus**® can provide two results per channel, and labs will see immediate benefits in doubling their qPCR system's usual output. We see endless possibilities for **PlexPlus**® application."

The data obtained within each channel at low or high temperature is discrete, with no cross talk. This simplifies result analysis for laboratories, removing the need for complex algorithms to ascertain contributions from different targets measured at the same wavelength.

RespiV **PlexPlus**®, the first product to harness this next generation multiplexing technology, simultaneously detects 14 respiratory viral targets in a single well, namely influenza A virus, influenza B virus, severe acute respiratory syndrome coronavirus 2, respiratory syncytial viruses A and B, adenoviruses B and C, human parainfluenza viruses 1, 2, 3 and 4, human metapneumovirus, rhinovirus and human enterovirus. This is the first of many products powered by **PlexPlus**® technology coming through the SpeedX pipeline.

"The RespiV **PlexPlus**® assay clearly discriminates between rhinovirus and enterovirus," states **Yin Xu, Research Manager, SpeedX**, "which will please laboratories that have been requesting this for some time".

"The launch of RespiV **PlexPlus**® is an exciting development! The ability to identify many targets in a single well can really improve workflow efficiency. This, along with compatibility with a wide range of qPCR systems commonly found in laboratories means that the labs can't wait to get their hands on it," says **Colin Denver, Chief Executive Office, SpeedX**, jovially. "Well, now the wait is over!"

About SpeedX Pty Ltd

Founded in 2009, SpeedX is a global company with offices in Austin, London and Sydney, and distributors across Europe. SpeedX specializes in molecular diagnostic solutions that go beyond simple detection to also offer comprehensive information on antibiotic resistance. Innovative real-time polymerase chain reaction (qPCR/NAAT) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. For more information on SpeedX please see: <https://plexpcr.com>

*Research Use Only, not for use in diagnostic procedures

Contact:

Michelle Howie
Associate Director | Global Strategic Marketing
michelleh@speedx.com.au
+61 499 743 199